Browse all 651 ETFs by category, no search needed
Global 185
US market 62
Country 93
Core UCITS 15
Sector 103
Style & factor 111
Theme 45
Dividend 37
ARK Genomic Revolution (ARKG)
Look-through valuation · Theme · Expense ratio 0.75 % · ISIN US00214Q3020
Price history (since 2014)
Monthly close since 2014. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| 10X Genomics Inc TXG | 9.5 % | −71.3 % | 66 |
| Twist Bioscience Corp TWST | 9.4 % | n/a | n/a |
| Tempus AI, Inc. Class A Common Stock TEM | 8.9 % | n/a | n/a |
| Crispr Therapeutics AG CRSP | 5.8 % | −70.1 % | 30 |
| Personalis Inc PSNL | 5.1 % | n/a | n/a |
| Absci Corp ABSI | 4.8 % | n/a | n/a |
| Guardant Health Inc GH | 4.7 % | n/a | n/a |
| Natera Inc NTRA | 4.2 % | −94.3 % | 37 |
| Illumina Inc ILMN | 4.1 % | +10.0 % | 80 |
| CareDx Inc CDNA | 3.8 % | −77.2 % | 68 |
| Eli Lilly and Company LLY | 3.5 % | −31.2 % | 69 |
| Compass Pathways Plc CMPS | 3.2 % | n/a | n/a |
| Schrodinger Inc SDGR | 3.1 % | −77.4 % | 58 |
| Beam Therapeutics Inc BEAM | 3.1 % | −59.3 % | 46 |
| Recursion Pharmaceuticals Inc RXRX | 2.6 % | −79.6 % | 22 |
| Adaptive Biotechnologies Corp ADPT | 2.4 % | n/a | n/a |
| GeneDx Holdings Corp. WGS | 2.3 % | −88.0 % | 52 |
| Nurix Therapeutics Inc NRIX | 2.0 % | n/a | n/a |
| Veracyte Inc VCYT | 2.0 % | +8.8 % | 70 |
| Arcturus Therapeutics Holdings Inc ARCT | 1.9 % | −51.3 % | 41 |
| Butterfly Network Inc BFLY | 1.8 % | n/a | n/a |
| Ionis Pharmaceuticals Inc IONS | 1.8 % | n/a | n/a |
| Alamar Biosciences, Inc. Common Stock ALMR | 1.6 % | n/a | n/a |
| Intellia Therapeutics Inc NTLA | 1.5 % | −82.4 % | 32 |
| Generate Biomedicines, Inc. Common Stock GENB | 1.3 % | n/a | n/a |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 32 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +87.2 % below FV
- 2 FXI iShares China Large-Cap ETF +57.2 % below FV
- 3 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +43.7 % below FV
- 4 MCHI iShares MSCI China ETF +41.9 % below FV
- 5 ITB iShares U.S. Home Construction ETF +31.4 % below FV
- 6 TAN Invesco Solar ETF +26.0 % below FV
- 7 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +19.4 % below FV
- 8 FDNI First Trust Dow Jones International Internet ETF +19.3 % below FV
- 9 ESPO VanEck Video Gaming and eSports ETF +18.3 % below FV
- 10 XIDV Franklin International Dividend Booster Index ETF +17.9 % below FV
Frequently asked about ARKG
Is ARKG overvalued?
How do you calculate the fair value of an ETF?
Which stocks drive the valuation of ARKG?
What is the expense ratio of ARKG?
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives ARK Genomic Revolution ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Sep 25, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.